Recon: Trump preparing order to cut federal health workforce; J&J inks $14B deal with Intra-Cellular
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- White House Preparing Order to Cut Thousands of Federal Health Workers (WSJ) (Reuters)
- The CRISPR companies are not OK (STAT)
- Letter to FDA’s Office of Prescription Drug Promotion, CDER (The Partnership for Safe Medicines)
- J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker (Endpoints)
- Trump team considers demanding WHO reform, including American in charge (Reuters)
- Trump faces pressure from US industry over China tariff on medicines (Reuters)
- HHS Website Went Down Following Communications Freeze (Bloomberg)
- Argentina says it will withdraw from the World Health Organization, echoing Trump (STAT)
- AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal (Endpoints)
- Africa's top health official presses US to resume health aid (Reuters)
- AstraZeneca shares rise as China probe update reassures (Reuters)
- IHH Healthcare's unit seeks up to $1.25 billion from Japan's Daiichi over Fortis deal (Reuters)
- Modified Dermatology App Now Escapes Ban As German Court Cases Continue (MedTech Insight)
- A $50B Market in Waiting: Medtech Trends To Watch Out For In 2025 In India (MedTech Insight)
- CAR-T cells can arm other immune cells with engineered proteins to fight cancer, study says (STAT)
- Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance (STAT)
- Personalized cancer vaccine shows potential in kidney cancer (STAT)
- Pfizer hires Novartis oncology exec to steer its cancer ambitions (Endpoints)
- Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff (Endpoints)
- AffyImmune’s layoffs; Henlius makes a biosimilar deal with Dr. Reddy’s (Endpoints)
- Lilly's profit forecast bring investors some relief amid Zepbound miss (Reuters)
- Becton looks to separate biosciences and diagnostic solutions after upbeat quarterly results (Reuters)
- Wegovy maker Novo Nordisk says surging growth driving emissions higher (Reuters)
- Bausch + Lomb Sale Stumble Frustrates Bausch Health Investors (Bloomberg)
- New Teladoc, same acquisition strategy (STAT)
- Digital health dealmaking is heating up (Endpoints)
- Siemens Healthineers says it would welcome stake reduction by Siemens (Reuters)
- Zimmer touts ASC opportunity with Paragon 28 purchase (MedTech Dive)
- AHA joins call for Trump to exempt devices from import tariffs (MedTech Dive)
- Medtronic’s Orleigh Bogle on changing the culture of surgical training (MedTech Dive)
- Boston Scientific closes its year of PFA on a high note (MedTech Dive)
- Illumina placed on China’s unreliable entity list (MedTech Dive)
- Pulse Biosciences names new CFO, continuing string of C-suite changes (MedTech Dive)
- Legal Overview Of MDR’s ‘Overly Broad And Vague Article 10a’ (MedTech Insight)
- US FDA’s Absence Raises Concerns In International Standards Development (MedTech Insight)
- USDA milk testing shows different strain of H5N1 bird flu in Nevada dairy herds (STAT)
- We are all complicit in the big lie of health insurance (STAT)
- FDA clinical trial inclusivity guidelines will be back (STAT)
- What happens when a rare disease drug seems to work, but the health care system doesn’t? (STAT)
- FDA Tissue Biopsy Draft Guidance Could Boost Liquid Biopsy Adoption In Clinical Trials (MedTech Insight)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
